Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.
This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.
Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.
Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company will engage in a fireside chat on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). In addition to the chat, Theravance Biopharma's senior management team will be available for one-on-one meetings with investors during the conference.
Interested parties can access the webcast or schedule meetings with the management team by contacting their BTIG representative or emailing uscorporateaccess@btig.com. This event provides an opportunity for investors to gain insights into Theravance Biopharma's current activities and future plans directly from the company's leadership.
Theravance Biopharma (NASDAQ: TBPH) has announced that it will release its second quarter 2024 financial results after market close on August 5, 2024. The company will also provide a business update during this report. Following the release, Theravance Biopharma will host a conference call and simultaneous webcast at 5:00 pm ET (2:00 pm PT/10:00 pm IST) on the same day.
Interested parties can pre-register for the telephone conference call or access the live webcast through the Investors section of Theravance Biopharma's website. A replay of the webcast will be available on the company's website for 30 days, until September 4, 2024.
Theravance Biopharma (NASDAQ: TBPH) reported first-quarter 2024 financial results, highlighting YUPELRI® sales of $55.2 million, an 18% increase year-over-year. Collaboration revenue with Viatris rose by 39% to $14.5 million. The company's Q1 ending cash balance was $100 million. R&D and SG&A expenses decreased to $9 million and $16.7 million, respectively. Theravance also reported a net loss of $11.7 million, down from $22.1 million in Q1 2023. The company is progressing with the CYPRESS study for ampreloxetine and has a key opinion leader event scheduled for May 23, 2024.
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference and host in-person meetings with investors. The event will include a Fireside Chat on May 20 at 11:30 AM EDT. A webcast will be available on Theravance.com for 30 days.
FAQ
What is the current stock price of Theravance Bioph (TBPH)?
What is the market cap of Theravance Bioph (TBPH)?
